Plant Name: Phaseolus vulgaris
Taxonomic Information:
Plant ID: NPO4934
Plant Latin Name: Phaseolus vulgaris
Taxonomy Genus: Phaseolus
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3885
Plant-of-the-World-Online:
514191-1
Used in Medicines:
Country/Region:
Brazil; Turkey; Madagascar; Italy; South Africa; Lebanon; Indonesia; India; Mexico; Zimbabwe; Jordan; Swaziland; Angola; China; Russia; SpainTraditional Medicine System:
Unani; Indian Folk; TCM; Homeopathy; SiddhaMedicinal Functions:
Cancer; Diuretic; Homeopathy; Hypoglycaemic; Hypotensive; Miscellany; Narcotic
Geographical Distribution:
Brazil; Turkey; Madagascar; Italy; Bangladesh; Guinea; Nepal; Costa Rica; Mongolia; Ethiopia; Rwanda; Peru; Swaziland; Argentina; Bolivia; Cameroon; Nigeria; Ecuador; Turkmenistan; Belarus; Cuba; Venezuela; Zambia; Russia; Togo; Zimbabwe; China; Lebanon; Jordan; Haiti; Iraq; Kazakhstan; Tanzania; Spain; Ukraine; Uganda; Pakistan; Philippines; Indonesia; United States; Trinidad and Tobago; Australia; Thailand; Honduras; Dominican Republic; Jamaica; Angola; Myanmar; Chad; Mexico; Tajikistan; South Africa; India; Uzbekistan; Senegal; Vietnam; Colombia; Sri Lanka; Kenya; Nicaragua
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPER1; ADORA3; ADORA2A; ADORA1; | |
| BLM; ADK; HSD17B1; AOX1; | |
| AR; | |
| ESR1; ESR2; | |
| ESRRA; ESRRB; | |
| SHBG; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Small molecule receptor (family A GPCR) | GPER1 | G-protein coupled estrogen receptor 1 | Q99527 | CHEMBL5872 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Unclassified | SHBG | Testis-specific androgen-binding protein | P04278 | CHEMBL3305 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.977E-08 | 4.306E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 4.741E-08 | 9.384E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.091E-07 | 3.795E-04 | AR, ESR1, ESR2, ESRRA, ESRRB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 7.290E-07 | 9.338E-04 | ESR1, ESR2 |
| CC | GO:0044456; synapse part | GO:0048786; presynaptic active zone | 1.635E-06 | 1.618E-03 | ADORA1, ADORA2A, GPER1 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.861E-06 | 1.688E-03 | ADORA1, ADORA2A, ADORA3, AR, ESR1, ESR2, ESRRA, ESRRB, GPER1 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.186E-06 | 1.809E-03 | ADORA1, ADORA2A |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 3.142E-06 | 2.359E-03 | ADORA1, ADORA2A, CYP3A4, ESR1, GPER1, HSD17B1 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.370E-06 | 2.973E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 4.370E-06 | 2.973E-03 | AR, SHBG |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.055E-17 | 2.297E-13 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, GPER1, HSD17B1, SHBG |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 7.607E-05 | 3.119E-03 | GPER1, ESR1, ESR2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; AR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; AR; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; AR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; AR; ADORA2A; ADK; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; AR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; AR; ADORA3; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ADORA1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; ADORA1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
| NA: NA | Male hypogonadism | NA | AR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; AR; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; AR; ESRRA; |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; AR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; ESRRA; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
